Neurocrine rises after raising 2026 sales forecast for movement-disorder drug
NBIX•Neurocrine raised its 2026 Ingrezza net sales forecast to $2.9 billion-$2.925 billion from $2.825 billion-$2.875 billion. Third-quarter revenue was $1.12 billion, above analysts’ $1.04 billion estimate, while Ingrezza sales rose 17% to $801 million.
1. Higher sales forecast
Neurocrine raised its 2026 net product sales forecast for Ingrezza to $2.9 billion-$2.925 billion, from $2.825 billion-$2.875 billion. Third-quarter revenue was $1.12 billion, compared with analysts’ $1.04 billion estimate, and Ingrezza sales increased 17% year over year to $801 million.
